A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
| Autor: | Fangzheng Wang, Fujun Hu, Bin Li, Tongxin Liu, Quanquan Sun, Jing Chen, Weifeng Qin, Zhimin Ye |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment concurrent chemoradiotherapy 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine IMRT Original Research Cisplatin Chemotherapy business.industry nasopharyngeal carcinoma medicine.disease Gemcitabine Concurrent chemoradiotherapy Regimen 030104 developmental biology Nasopharyngeal carcinoma Docetaxel Cancer Management and Research 030220 oncology & carcinogenesis Propensity score matching business neoadjuvant chemotherapy medicine.drug |
| Zdroj: | Cancer Management and Research |
| ISSN: | 1179-1322 |
| Popis: | Tongxin Liu,1–3,* Quanquan Sun,1,2,* Jing Chen,1–3 Fangzheng Wang,1–3 Bin Li,1–3 Weifeng Qin,1–3 Zhimin Ye,1–3 Fujun Hu1–3 1Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China; 2Key Laboratory of Radiation Oncology in Zhejiang Province, Hangzhou, China; 3Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Hangzhou, China *These authors contributed equally to this work Purpose: To compare the efficacy and safety of neoadjuvant chemotherapy (NACT) with gemcitabine (GEM) vs docetaxel plus cisplatin (CDDP) in locoregionally advanced nasopharyngeal carcinoma (NPC).Methods: A total of 222 patients with locoregionally advanced NPC between February 2012 and May 2014 in our hospital who received NACT with GEM or docetaxel plus CDDP combined with concurrent chemoradiotherapy (CCRT) were retrospectively analyzed. Fifty-two patients treated with GEM plus CDDP (GP) combined with CCRT were matched with 52 patients who received docetaxel plus CDDP (TP) combined with CCRT.Results: With a median follow-up time of 60 months (range, 14–72 months), the 5-year overall survival, progression-free survival (PFS), local relapse-free survival and distant metastasis-free survival (DMFS) rates were 78.8%, 66.0%, 81.0% and 75.9%, respectively, in the GP group and 79.4%, 60.5%, 79.6% and 73.6%, respectively, in the TP group. No statistically significant survival differences were found between the two groups. In multivariate analysis, T3–4 and N2–3 were prognostic factors for poor 5-year PFS and DMFS (all P-values 0.05).Conclusion: NACT with GP or TP regimen achieved comparable clinical outcome with acceptable toxicities. Both regimens might be a treatment option for patients with locoregionally advanced NPC. Keywords: nasopharyngeal carcinoma, IMRT, neoadjuvant chemotherapy, concurrent chemoradiotherapy |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|